Education
About Us
Working with TipRanks
Follow Us
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
Total Valuation
Sonoma Pharmaceuticals has a market cap or net worth of $3.96M. The enterprise value is -$1.18M.
Market Cap$3.96M
Enterprise Value-$1.18M
Share Statistics
Sonoma Pharmaceuticals has 1.62M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1.62M
Owned by Insiders31.44%
Owned by Instutions0.64%
Financial Efficiency
Sonoma Pharmaceuticals’s return on equity (ROE) is -0.79 and return on invested capital (ROIC) is -38.48%.
Return on Equity (ROE)-78.78%
Return on Assets (ROA)-32.80%
Return on Invested Capital (ROIC)-38.48%
Return on Capital Employed (ROCE)-42.65%
Revenue Per Employee$1,058,200
Profits Per Employee-$260,500
Employee Count10
Asset Turnover0.86
Inventory Turnover2.94
Valuation Ratios
The current PE Ratio of Sonoma Pharmaceuticals is -0.58. Sonoma Pharmaceuticals’s PEG ratio is <0.01.
PE Ratio-0.58
PS Ratio0.22
PB Ratio0.45
Price to Fair Value0.45
Price to FCF-1.15
Price to Operating Cash Flow-1.16
PEG Ratio<0.01
Income Statement
In the last 12 months, Sonoma Pharmaceuticals had revenue of $10.58M and earned -$2.60M in profits. Earnings per share was -$2.59.
Revenue$10.58M
Gross Profit$3.72M
Operating Income-$3.29M
Pretax Income-$2.74M
Net Income-$2.60M
EBITDA-3.21M
Earnings Per Share (EPS)-2.59
Cash Flow
In the last 12 months, operating cash flow was $1.07M and capital expenditures -$25.00K, giving a free cash flow of $1.05M billion.
Operating Cash Flow$1.07M
Free Cash Flow$1.05M
Free Cash Flow per Share$0.65
Dividends & Yields
Sonoma Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-86.82%
Earnings Yield-173.82%
Stock Price Statistics
Beta2.07
52-Week Price Change-21.69%
50-Day Moving Average2.60
200-Day Moving Average3.48
Relative Strength Index (RSI)52.40
Average Volume (3m)3.16M
Important Dates
Sonoma Pharmaceuticals upcoming earnings date is Jul 9, 2025, After Close.
Last Earnings DateFeb 5, 2025
Next Earnings DateJul 9, 2025
Ex-Dividend Date―
Financial Position
Sonoma Pharmaceuticals as a current ratio of 3.37, with Debt / Equity ratio of 0.10
Current Ratio3.37
Quick Ratio2.64
Debt to Market Cap0.19
Net Debt to EBITDA0.56
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sonoma Pharmaceuticals has paid -$136.00K in taxes.
Income Tax-$136.00K
Effective Tax Rate3.90%
Enterprise Valuation
Sonoma Pharmaceuticals EV to EBITDA ratio is -0.06, with an EV/FCF ratio of -0.11.
EV to Sales0.02
EV to EBITDA-0.06
EV to Free Cash Flow-0.11
EV to Operating Cash Flow-0.11
Balance Sheet
Sonoma Pharmaceuticals has $5.24M in cash and marketable securities with $119.00K in debt, giving a net cash position of -$5.12M billion.
Cash & Marketable Securities$5.24M
Total Debt$119.00K
Net Cash-$5.12M
Net Cash Per Share-$3.17
Tangible Book Value Per Share$6.75
Margins
Gross margin is 37.26%, with operating margin of -36.91%, and net profit margin of -37.97%.
Gross Margin37.26%
Operating Margin-36.91%
Pretax Margin-39.51%
Net Profit Margin-37.97%
EBITDA Margin-35.53%
EBIT Margin-36.91%
Analyst Forecast
The average price target for Sonoma Pharmaceuticals is , which is 11.43% higher than the current price. The consensus rating is
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast13.51%
EPS Growth Forecast78.93%